Skip to main content

Following Spring Cleaning, Paradigm Genetics Posts Increased Losses, Lower Revenues

NEW YORK, Aug. 12-Paradigm Genetics today reported increased losses and declining revenues for the second quarter of 2002.

 

Net loss for the quarter was $5 million or $0.16 per share, compared to a net loss of $4.3 million or $0.16 per share in the same quarter of 2001.

 

Revenues fell by 13 percent to $5.3 million for the quarter from $6.1 million in the first quarter of 2001, a slump caused by a slowdown in Paradigm's commercial partnership with Bayer. The company said this decline was partly offset by new revenues from its December 2001 purchase of the plant genomics firm ParaGen.

 

Including stock-based compensation expenses, the company spent $7.6 million on R&D in the quarter, up from $6.9 million in the second quarter last year.

 

As of June 30, 2002, Paradigm held $9.6 million in cash, cash equivalents and short-term investments.

 

Earlier this spring, Paradigm launched a house-cleaningthat laid off 20 percent of the workforce and replaced founder and CEO John Ryals with Syngenta executive Heinrich Gugger.

The Scan

Pfizer-BioNTech Seek Full Vaccine Approval

According to the New York Times, Pfizer and BioNTech are seeking full US Food and Drug Administration approval for their SARS-CoV-2 vaccine.

Viral Integration Study Critiqued

Science writes that a paper reporting that SARS-CoV-2 can occasionally integrate into the host genome is drawing criticism.

Giraffe Species Debate

The Scientist reports that a new analysis aiming to end the discussion of how many giraffe species there are has only continued it.

Science Papers Examine Factors Shaping SARS-CoV-2 Spread, Give Insight Into Bacterial Evolution

In Science this week: genomic analysis points to role of human behavior in SARS-CoV-2 spread, and more.